The Relative Strength (RS) Rating for Plexus moved up into a higher percentile Thursday, as it got a lift from 65 to 71.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks typically have an 80 or higher RS Rating in the early stages of their moves. See if Plexus can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Plexus is not currently showing a potential buy point. See if the stock goes on to build a promising consolidation that could kick off a new price move.
In terms of top and bottom line numbers, Plexus has posted rising EPS growth in each of the last three reports. Top line growth has not followed the same trajectory, coming in at -1% in the latest report.
The company earns the No. 8 rank among its peers in the Electronics-Contract Manufacturing industry group. Celestica, Fabrinet and Flex Ltd are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
